The potential use of stem cells derived from human amniotic fluid in renal diseases

Imagem de Miniatura
Arquivos
art_NORONHA_The_potential_use_of_stem_cells_derived_from_2011.PDF (360.32 KB)
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
DUARTE, Sergio A.
Citação
KIDNEY INTERNATIONAL SUPPLEMENTS, v.1, n.3, p.77-82, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Amniotic fluid (AF) contains a variety of cell types derived from fetal tissues that can easily grow in culture. These cells can be obtained during amniocentesis for prenatal screening of fetal genetic diseases, usually performed during the second trimester of pregnancy. Of particular interest, some expanded sub-populations derived from AF cells are capable of extensive self-renewal and maintain prolonged undifferentiated proliferation, which are defining properties of stem cells. These human AF stem cells (hAFSCs) exhibit multilineage potential and can differentiate into the three germ layers. They have high proliferation rates and express mesenchymal and embryonic markers, but do not induce tumor formation. In this study, hAFSCs derived from amniocentesis performed at 16-20 weeks of pregnancy were isolated, grown in culture, and characterized by flow cytometry and by their potential ability to differentiate into osteogenic, adipogenic, and chondrogenic lineages. After 4-7 passages, 5 x 10(5) hAFSCs were inoculated under the kidney capsule of Wistar rats that were subjected to an experimental model of chronic renal disease, the 5/6 nephrectomy model (Nx). After 30 days, Nx rats treated with hAFSCs displayed significant reductions in blood pressure, proteinuria, macrophages, and a-smooth muscle actin expression compared with Nx animals. These preliminary results suggest that hAFSCs isolated and expanded from AF obtained by routine amniocentesis can promote renoprotection in the Nx model. Considering that the AF cells not used for fetal karyotyping are usually discarded, and that their use does not raise ethical issues, they may represent an alternative source of stem cells for cell therapy and regenerative medicine.
Palavras-chave
amniotic fluid stem cells, chronic kidney disease, mesenchymal stem cells
URI
https://observatorio.fm.usp.br/handle/OPI/22616
Referências
  1. SEEDS AE, 1980, AM J OBSTET GYNECOL, V138, P575
  2. Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102
  3. Ye Z, 2008, HEPATOB PANCREAT DIS, V7, P608
  4. in 'tAnker PS, 2003, BLOOD, V102, P1548, DOI 10.1182/blood-2003-04-1291
  5. De Coppi P, 2007, J UROLOGY, V177, P369, DOI 10.1016/j.juro.2006.09.103
  6. Siegel N, 2010, HUM MOL GENET, V19, P3320, DOI 10.1093/hmg/ddq236
  7. Tsai MS, 2004, HUM REPROD, V19, P1450, DOI 10.1093/humrep/deh279
  8. Kim J, 2007, CELL PROLIFERAT, V40, P75
  9. Bossolasco P, 2006, CELL RES, V16, P329, DOI 10.1038/sj.cr.7310043
  10. Roubelakis MG, 2007, STEM CELLS DEV, V16, P931, DOI 10.1089/scd.2007.0036
  11. Caldas HC, 2008, TRANSPL P, V40, P853, DOI 10.1016/j.transproceed.2008.03.009
  12. Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005-0342
  13. Chiavegato A, 2007, J MOL CELL CARDIOL, V42, P746, DOI 10.1016/j.yjmcc.2006.12.008
  14. Fauza D, 2004, BEST PRACT RES CL OB, V18, P877, DOI 10.1016/j.bpobgyn.2004.07.001
  15. Valli A, 2010, ONCOGENE, V29, P966, DOI 10.1038/onc.2009.405
  16. Siegel N, 2009, REPROD BIOMED ONLINE, V19, P838
  17. Prusa AR, 2003, HUM REPROD, V18, P1489, DOI 10.1093/humrep/deg279
  18. Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9
  19. Perin L, 2007, CELL PROLIFERAT, V40, P936, DOI 10.1111/j.1365-2184.2007.00478.x
  20. Cavaglieri RC, 2009, TRANSPL P, V41, P947, DOI 10.1016/j.transproceed.2009.01.072
  21. Casiraghi F, 2008, J IMMUNOL, V181, P3933
  22. Baxter MA, 2004, STEM CELLS, V22, P675, DOI 10.1634/stemcells.22-5-675
  23. Da Sacco S, 2010, J UROLOGY, V183, P1193, DOI 10.1016/j.juro.2009.11.006
  24. Sessarego N, 2008, HAEMATOL-HEMATOL J, V93, P339, DOI 10.3324/haematol.11869
  25. De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
  26. Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559
  27. BRACE RA, 1986, SEMIN PERINATOL, V10, P103
  28. DUENHOELTER JH, 1976, AM J OBSTET GYNECOL, V125, P306
  29. GOSDEN CM, 1983, BRIT MED BULL, V39, P348
  30. HOEHN H, 1982, METHOD CELL BIOL, V26, P11
  31. MINEI LJ, 1976, OBSTET GYNECOL, V48, P177
  32. Perin L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009357
  33. PRIEST RE, 1978, LAB INVEST, V39, P106
  34. Prusa AR, 2002, MED SCI MONITOR, V8, pRA253
  35. Trounson A, 2007, NAT BIOTECHNOL, V25, P100
  36. Underwood Mark A, 2005, J Perinatol, V25, P341, DOI 10.1038/sj.jp.7211290

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/29
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - LIM/57